Caenorhabditis elegans contains 3 homologs of presenilin genes that are associated with Alzheimer's disease. Loss-offunction mutations in C. elegans genes cause a defect in egg laying. In humans, loss of presenilin-1 (PS1) function reduces amyloid-beta peptide processing from the amyloid protein precursor. Worms were screened for compounds that block egg laying, phenocopying presenilin loss of function. To accommodate even relatively high throughput screening, a semiautomated method to quantify egg laying was devised by measuring the chitinase released into the culture medium. Chitinase is released by hatching eggs, but little is shed into the medium from the body cavity of a hermaphrodite with an egg laying deficient (egl) phenotype. Assay validation involved measuring chitinase release from wild-type C. elegans (N2 strain), sel-12 presenilin loss-of-function mutants, and 2 strains of C. elegans with mutations in the egl-36 K + channel gene. Failure to find specific presenilin inhibitors in this collection likely reflects the small number of compounds tested, rather than a flaw in screening strategy. Absent defined biochemical pathways for presenilin, this screening method, which takes advantage of the genetic system available in C. elegans and its historical use for anthelminthic screening, permits an entry into mechanismbased discovery of drugs for Alzheimer's disease. (Journal of Biomolecular Screening 2004:147-152) 
INTRODUCTION
A LZHEIMER'S DISEASE (AD) causes progressive dementia associated with formation of amyloid plaques and neurofibrillary tangles, accompanied by gliosis and neuronal loss. Mutations in 3 genes cause an autosomal dominant form of the disease. 1 These genes encode the amyloid protein precursor (APP) and a pair of related proteins, presenilin-1 (PS1) and presenilin-2 (PS2). Mutations in any of the 3 enhance proteolytic processing of APP via an intracellular pathway that produces amyloid β-peptide, a 40-42 amino acid long peptide that is the primary component of amyloid plaque in AD. 2, 3 Formation of the 42 amino acid forms of the peptide is associated with accelerated AD pathogenesis. Mutations in APP, PS1, or PS2 increase the ratio of Aβ1-42 relative to total Aβ peptide production by subtly altering the site of proteolytic processing. 3 Insight into presenilin function has come from studies of genes encoding presenilin homologs in model organisms such as the free-living nematode, Caenorhabditis elegans, and from engineered deletions of the PS1 gene in mice. Three presenilin genes have been identified in C. elegans: sel-12, hop-1, and spe-4. [4] [5] [6] [7] Loss-of-function mutations in sel-12 cause a defect in egg laying, which can be rescued by human PS1 or PS2, demonstrating that features of the presenilin protein required for function have been conserved between nematodes and humans. 5, 8 Sel-12 has been shown to be required for signaling mediated by the C. elegans Notch receptor homologs, lin-12 and glp-1. 5 Loss of sel-12 function suppresses lin-12 gain-of-function phenotypes and enhances lin-12 and glp-1 partial loss-of-function phenotypes. 5, 9 A link between PS1 function and Notch pathway signaling is also suggested by the phenotype of PS1 null mouse embryos. These show altered spatiotemporal expression of Notch1 with accompanying defects in somite segmentation and differentiation. 10 More interesting from the perspective of AD pathophysiology, neurons cultured from PS1 null embryos have defects in amyloidogenic processing of APP. 11 Thus, presenilin function is a potential target for therapeutic intervention in AD.
To enable proof-of-concept studies for this target for AD therapy, we sought to design a screen for inhibitors of presenilin function. As the biochemistry of presenilin function remains obscure, a focused, mechanism-based high-throughput screening (HTS) strategy was not feasible. Instead, we devised a screen using C. elegans to identify potential presenilin inhibitors. Based on available genetic analyses, compounds were sought that phenocopy the egg-laying defect associated with loss of presenilin function. As the classical method to evaluate this phenotype involves microscopic enumeration of shed eggs, we also needed to identify a marker for egg laying suitable for incorporation into a reasonably high-throughput screening program.
MATERIALS AND METHODS

Strains
The N2 wild-type strain of C. elegans was purchased from the Caenorhabditis Genetics Center, University of Minnesota. The n728 (DT6716) and n2332 (MT6011) alleles of egl-36 alter Kv3 potassium channel function and cause a partial egl phenotype; this is traced to defects in the ability of the enteric and egg-laying muscles to contract. 12 These strains were also purchased from the Caenorhabditis Genetics Center. The sel-12 (GS1214) strain of C. elegans was a gift from Dr. Iva Greenwald, Columbia University. Lin-12(d) worms carry an activating mutation in the lin-12 receptor, which causes them to be egl. 13 This strain was purchased from the Caenorhabditis Genetics Center.
Screening plates
Drug exposure took place in 96-well microplates. Each well contained a total volume of 200 µl, including 161 µl of culture medium (M-9 buffer + E. coli broth), 6 µl M-9 buffer, 30% DMSO in M-9 buffer or drug dissolved in 30% DMSO at 300 µM, and 33 µl of worms from synchronized cultures 14 in M-9 buffer (50-90 individuals). Drugs were tested in duplicate. Some of the initial characterization with the DT6716, MT0611, GS1214, and N2 C. elegans strains was done with unsynchronized cultures. Six days later, the worms were fed 7 µl E. coli broth (3 days after inoculation) to ensure reproduction. Concentration-response tests with selected compounds were performed over the range 0.3-10 µM. DMSO concentration was held constant in all cases. The medium volume was 147 µl, and the drug volume was 20 µl. Worms were added in 33 µl aliquots as above.
Chitinase assay
Chitinase activity was determined when gravid worms and L1 larvae were evident. The fluorogenic chitinase substrate (10 µl 0.8 mM of 4-methylumbelliferyl-β-D-N,N′,N″-triacetylchito-trioside in DMSO, Sigma Chemical Co., St. Louis, MO) was added to each well of the 96-well plates and incubated at 37°C for 1 h. The assay was terminated by the addition of 100 µl alkaline buffer (1 M glycine/1 N NaOH, pH 10.6). Wells were read on a fluorimeter 15, 16 at excitation 360/40, emission 460/40, gain 75.
RESULTS
Validation of the chitinase assay
Reducing or eliminating sel-12 activity causes a defect in egg laying in C. elegans. In egl worms, eggs hatch inside the adult hermaphrodite and develop within the body cavity. This kills the adult hermaphrodite, which eventually releases L1-or L2-stage larvae into the culture. Chitinase is released from the egg, is stable, and accumulates over several days in culture medium from parasitic nematodes. 16 Release of chitinase is linear with the number of eggs hatched per well. We tested 2 substrates, MeUmb-(GlcNac) 2 and MeUmb-(GlcNAc) 3 , to measure chitinase release from wild-type N2 worms and 2 egl mutants, sel-12 and egl-36 (DT 6716). Worms were plated with E. coli in 96-well plates and allowed to develop for 10 days in asynchronous culture. Fluorescent yield using MeUmb-(GlcNAc) 3 was 60% higher than that seen with MeUmb-(GlcNAc) 2 , so the trimeric substrate was chosen for use in the plate assay. Release of chitinase into cultures of egl-36 and sel-12 worms was reduced by 48% and 76%, respectively, compared to the cultures containing similar numbers of N2 worms (2-tailed Student's t-test, P < 0.001) ( Fig. 1) . Presumably, the body wall or psuedocoelom of worms retains or inactivates most of the chitinase released from eggs hatched within the adult. Thus, chitinase released in the 96-well plate assay should provide an efficient means to screen for compounds that inhibit egg laying by C. elegans. 
N2 screen for compounds causing a defect in egg laying
We screened 10,780 compounds from the legacy Pharmacia Research Compound Collection for reduction of chitinase levels in cultures of the N2 strain. Examples of the primary screening data are presented in Figures 2A and 2C . The mean and variance differed between experiments. Cutoff values for selection of hits were based on the statistics of the distribution with a threshold of z ≥ 3.0 (P < 0.001; Figs. 2B and 2D). The primary screen yielded 37 hits, of which 16 replicated on rescreening. Visual examination was used to eliminate compounds that decreased worm viability and allowed E. coli overgrowth. Efficacy of the 16 compounds ranged from 49% to 87% inhibition of chitinase release (10 µM). Seven of the compounds had IC 50 values < 3µM. Concentration-response curves for representative compounds are shown in Figure 3 . To test for direct effects of on chitinase activity, compounds were incubated with worm-free supernatants from N2 cultures containing hatched eggs. None inhibited chitinase activity (data not shown).
lin-12(d) screen for compounds that can restore egg laying
The lin-12(d) mutation activates lin-12 signaling through the lin-12/Notch pathway, producing an egl phenotype that is partially rescued by sel-12 loss-of-function mutations. 5, 13 We screened 1700 compounds from the same collection and the 16 hits from the N2 screen for ability to increase chitinase activity in cultures of the lin-12 strain of C. elegans. Release of chitinase from lin-12(d) worms averaged 5893 ± 902 SD fluorescence units (FU). The data were distributed in a Gaussian distribution, so that compounds that increase chitinase 1.4-fold would differ significantly from background (P < 0.01). From the primary screen, 30 compounds were identified that exceeded that threshold. Eleven confirmed in repeat assays. Only 3 stimulated chitinase release 2-fold above background. This compares to the release of chitinase from N2 worms, which averages 16,000-25,000 FU under the conditions of the assay, a difference of 3-to 4-fold. Thus, the best compounds restored chitinase release to levels lower but approaching those seen in N2 worms. However, despite the positive effect on release of chitinase activity, visual examination showed that the compounds did not restore egg laying. The number of eggs per well in drug-treated cultures was not different from that seen in DMSO-treated control cultures of lin-12(d) worms (data not shown).
sel-12 lethal screen for compounds reducing presenilin activity
Coincident loss-of-function mutations in sel-12 and hop-1 result in embryonic lethality. We sought to screen for compounds lethal to sel-12 worms but not wild-type N2 worms as another way to identify compounds that inhibit presenilin function. However, it proved difficult to synchronize the sel-12 strain. Instead, we assayed a small number of hits from the N2 screen on asynchronous sel-12 worms grown on soft agar in 35 mm dishes. One compound caused an interesting malformation of eggs developing within the gonad of sel-12 hermaphrodites. Rather than the normal linear array of well-formed eggs, eggs in sel-12 worms treated with this compound were larger and lacked definition. Two other compounds reduced the numbers of eggs in sel-12 hermaphrodites, and those remaining were larger than normal. Three compounds had no obvious effect.
DISCUSSION
Although there is good evidence to support the hypothesis that altered presenilin function underlies at least some cases of AD, the complete biological role of the presenilins has not been elucidated. Multiple presenilin mutations are associated with autosomaldominant forms of familial AD and are characterized by increased relative abundance of amyloidogenic fragments of APP. 3 These data were interpreted to support the concept that amino acid substitutions generate gain-of-function mutations in presenilin. 8 Subsequent analysis of the function of presenilin mutants in C. elegans and mammalian cells has not completely resolved the question of whether AD-associated mutations are gain-of-function or loss-offunction in effect. 8, [17] [18] [19] Although model organisms such as C. elegans are of indisputable value in unraveling the basic biology of diseases like AD, [20] [21] [22] a full understanding of the role of presenilins in human AD requires small molecules that can either enhance or inhibit their activity. Lacking the ability to screen for such molecules in a biochemically defined format, we instead devised a screening strategy that employed C. elegans. Our 1st goal was to discover small molecules that selectively inhibit presenilin function in this nematode; such compounds could then be followed up in human cells in cultures to determine their influence on Aβ 1-42 production. The choice of C. elegans for this role is justified by its long history as a model organism for anthelmintic discovery. 23, 24 Testing tens of thousands of random compounds requires an assay capable of relatively high throughput. The most obvious phenotype associated with reduced sel-12 function in C. elegans is diminished egg laying (the egl phenotype), although the product of this gene is also required for morphology and function of thermosensory neurons in C. elegans. 25 Egg laying is typically assessed by microscopic evaluation of the number of eggs present on an agar plate in a specified time period. We sought to develop a semiautomated method that would quantify egg laying by measuring a biochemical surrogate. Studies on the parasitic nematode, Heligmosomoides polygyrus, showed that chitinase activity was released into the culture medium as eggs hatched and that the activity was stable and accumulated over time. 16 We demonstrated that the accumulation of chitinase in medium obtained from cultures of several different egl strains was much lower than enzyme levels observed in culture medium from equivalent numbers of N2 worms. Although a basal level of chitinase activity was present even in strains that shed no eggs, the difference in levels between wild-type and completely egl strains was of sufficient magnitude to be useful for screening. The data suggest that measurements of chitinase activity in culture supernatants provide an indication of egg laying; little chitinase is released from eggs hatched inside the parent hermaphrodite into the medium. That strains with partial egl characteristics had intermediate levels of chitinase activity supports this contention. The assay was reproducible and robust and was used as the basis for screening for compounds that inhibit egg laying in N2 worms. The behavior of egg laying is known to be influenced by many genes other than sel-12. 26, 27 In addition, nematotoxins and compounds that inhibit egg hatching per se as opposed to egg laying will be false positives. Therefore, we assumed that only a minority of compounds that inhibit egg laying would act by inhibiting presenilin function. The addition of 2 other C. elegans-based screens enabled us to distinguish hits from the primary screen that act on presenilin rather than other proteins that regulate this behavior. The secondary screens included an assay using a lin-12(d) strain to identify compounds that restore egg laying, and a sel-12 selective lethality screen. These screens take advantage of the extensive genetic information available about the lin-12/Notchsignaling pathway in C. elegans. For instance, gain-of-function mutations in the lin-12 gene (eg, lin-12(d) 9 ) reduce egg laying by causing structural abnormalities in the gonad and vulva, and this phenotype is suppressed in the presence of loss-of-function mutations in sel-12. 5 Thus, compounds that mimic loss-of-function mutations in sel-12 should restore egg laying to a lin-12 (d) strain, whereas compounds that act on a different target to inhibit egg laying should only enhance the egl phenotype in this strain. The reversal of effect, from inhibition of egg laying in N2 worms to restoration of egg laying in the lin-12(d) strain, is an exceptionally powerful test of specificity. It should be noted that it is not surprising that the indirect measurement of egg laying (chitinase activity) can result in false positives. For instance, compounds that inhibit protease-mediated degradation of chitinase or that increase the permeability of worms should raise chitinase levels in culture medium without affecting egg laying.
The other secondary assay was based on the fact that the phenotype of sel-12 mutant worms is exacerbated by coincident loss-offunction mutations in hop-1, a 2nd C. elegans presenilin gene that, to some extent, is functionally redundant with sel-12. 6, 7 Hop-1 loss-of-function mutations in sel-12 null worms are lethal, although null mutants of hop-1 are not egl. One can view these phenotypes as representing a spectrum of reductions in total presenilin function. Compounds that specifically inhibit presenilin should inhibit egg laying in N2 worms but would be expected to be toxic to a sel-12 null strain, as the overall level of presenilin activity should be reduced to the point of lethality. Again, the specific prediction of strain-dependent effects of true presenilin inhibitors provides a stringent criterion for test compounds to pass prior to progressing to assays using mammalian systems.
Although we readily found compounds that phenocopied sel-12 loss-of-function mutations by reducing chitinase release, none was active in the lin-12(d) or sel-12 lethal screens. Similarly, although we found compounds that restored chitinase release from lin-12(d) mutants, none was active in the N2 screen. The active compounds were not directly toxic to the worms, and so must act on nonpresenilin proteins involved in egg laying. Finally, our least successful screen was designed to identify compounds that were selectively lethal to sel-12 worms. It was abandoned due to the difficulty of procuring enough healthy worms for even a modestly high-throughput screen. That none of the test compounds passed the combination of assays is likely due more to the small numbers screened than to an inherent flaw in the screening strategy. The results of the limited operation of the screen suggest that it is a feasible approach to screening for compounds that affect targets of unknown function, such as presenilin.
